Pharmacological modulation of septins restores calcium homeostasis and is neuroprotective in models of Alzheimer's disease.
Alzheimer Disease
/ drug therapy
Animals
Septins
/ metabolism
Homeostasis
Mice
Calcium
/ metabolism
Disease Models, Animal
tau Proteins
/ metabolism
Neuroprotective Agents
/ pharmacology
Amyloid beta-Peptides
/ metabolism
Humans
Neuronal Plasticity
/ drug effects
Calcium Signaling
/ drug effects
Calcium Channels
/ metabolism
Cytoskeleton
/ metabolism
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
30
5
2024
Statut:
ppublish
Résumé
Abnormal calcium signaling is a central pathological component of Alzheimer's disease (AD). Here, we describe the identification of a class of compounds called ReS19-T, which are able to restore calcium homeostasis in cell-based models of tau pathology. Aberrant tau accumulation leads to uncontrolled activation of store-operated calcium channels (SOCCs) by remodeling septin filaments at the cell cortex. Binding of ReS19-T to septins restores filament assembly in the disease state and restrains calcium entry through SOCCs. In amyloid-β and tau-driven mouse models of disease, ReS19-T agents restored synaptic plasticity, normalized brain network activity, and attenuated the development of both amyloid-β and tau pathology. Our findings identify the septin cytoskeleton as a potential therapeutic target for the development of disease-modifying AD treatments.
Identifiants
pubmed: 38815015
doi: 10.1126/science.add6260
doi:
Substances chimiques
Septins
EC 3.6.1.-
Calcium
SY7Q814VUP
tau Proteins
0
Neuroprotective Agents
0
Amyloid beta-Peptides
0
Calcium Channels
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM